The CDMO said that the facility was key in its first-quarter gains and will continue to be for the rest of the year. Although the South Korean company did not break down its revenue by facility, it said on Wednesday that much of its Q1 earnings at 946.9 billion Korean won ($690 million) were due to Plant 4 and its biosimilar business — a 31% increase from the 720.9 billion Korean won ($525 million) it reported in Q1 last year.
INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024.
INCHEON, South Korea, Feb. 13, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that it has received the Leadership status and A- rating from the Carbon Disclosure Project (CDP).
INCHEON, South Korea, Feb. 7, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced it has signed a partnership agreement with LegoChem Biosciences (KOSDAQ: 141080), a biotech company pioneering the research and development of antibody-drug conjugate (ADC) programs.
INCHEON, South Korea, Jan. 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced robust financial results for the fourth quarter and fiscal year 2023.
INCHEON, South Korea, Jan. 22, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced that the company was awarded the EcoVadis' Platinum Sustainability Rating, the highest recognition given, for the company's sustainability management.
INCHEON, South Korea, Jan. 9, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today presented its 2024 business plans and strategy at the J.P. Morgan Healthcare Conference held in San Francisco, California.
LOWELL, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the œCompany), an innovative life sciences technology company providing mission critical automation...
INCHEON, South Korea, Nov. 28, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract and development and manufacturing organization (CDMO), today hosted its inaugural Supplier ESG Day, both at its Songdo headquarters and online, to share environmental, social, and governance (ESG) strategies and drive collective action to decarbonize.